{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:36:27Z","timestamp":1785368187341,"version":"3.55.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunotherapy combined with chemotherapy has improved outcomes in advanced gastric cancer (GC), but reliable biomarkers to predict clinical benefit remain limited. Metabolomics provides a comprehensive assessment of systemic metabolic changes and may yield prognostic indicators to guide treatment selection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed untargeted liquid chromatography\u2013tandem mass spectrometry (LC-MS\/MS) metabolomics on baseline plasma from 40 patients with advanced GC receiving first-line programmed cell death protein-1 (PD-1) inhibitor plus chemotherapy. Patients were stratified into long-term survivors (LTS) and short-term survivors (STS) based on median overall survival (OS). Differential metabolites were identified using multivariate statistics, followed by univariate Cox regression and least absolute shrinkage and selection operator (LASSO) analysis to construct a metabolite-based risk score. Prognostic performance was evaluated using Kaplan-Meier analysis, time-dependent receiver operating characteristic (ROC) curves, and multivariate Cox models. Comparisons with conventional clinical factors were conducted, and a prognostic nomogram was developed. Proportional-hazards assumptions were assessed with Schoenfeld residuals; discrimination was optimism-corrected using 1,000-bootstrap resampling; Harrell\u2019s concordance index (C-index), time-dependent area under the curve (AUC), and bootstrap-corrected calibration curves were reported. Twelve-month decision-curve analysis (DCA) quantified net clinical benefit compared with clinicopathologic baselines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 4,298 metabolites were detected, including 830 Level 1 and 1,321 Level 2 identifications. Principal component analysis and orthogonal partial least squares discriminant analysis showed clear separation between LTS and STS groups. Differential analysis revealed metabolites enriched in bile acid, amino acid, and retinol metabolism pathways. Cox and LASSO analyses identified six independent prognostic metabolites. The resulting metabolite-based risk score significantly stratified OS and progression-free survival (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.01) and demonstrated stable predictive accuracy over 6\u201324 months. Compared with age, sex, tumor grade, and programmed death-ligand 1 combined positive score (PD-L1 CPS), the risk score showed superior discrimination. A nomogram integrating risk score, grade, and PD-L1 CPS yielded accurate OS predictions with strong calibration and higher net benefit in DCA. Internal validation supports the robustness of findings within this single-center, 40-patient cohort.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A plasma metabolite-based risk score derived from six biomarkers independently predicts survival in advanced GC treated with PD-1\u2013based immunotherapy and offers a practical tool for individualized prognosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1714472","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T07:49:40Z","timestamp":1770623380000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Identification of plasma lipidomic biomarkers for prognostic stratification in advanced gastric cancer treated with PD-1 inhibitor plus chemotherapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Zhouwei","family":"Zhan","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muqun","family":"He","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghong","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Gastric Surgical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiami","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanchen","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoting","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengqing","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e71065","DOI":"10.1002\/cam4.71065","article-title":"Current advances and future directions for sensitizing gastric cancer to immune checkpoint inhibitors","volume":"14","author":"Li","year":"2025","journal-title":"Cancer Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00747-0","article-title":"Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention","volume":"20","author":"Thrift","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e0320751","DOI":"10.1371\/journal.pone.0320751","article-title":"Long-term trends and projections of stomach cancer burden in China: Insights from the GBD 2021 study","volume":"20","author":"Zhan","year":"2025","journal-title":"PloS One"},{"key":"B4","doi-asserted-by":"publisher","first-page":"102245","DOI":"10.1016\/j.clinre.2023.102245","article-title":"New developments and standard of care in the management of advanced gastric cancer","volume":"48","author":"Depotte","year":"2024","journal-title":"Clinics Res Hepatol Gastroenterol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01601","article-title":"First-Line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-Year follow-Up of the phase III checkMate 649 trial","volume":"42","author":"Janjigian","year":"2024","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41419-025-07385-7","article-title":"Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies","volume":"16","author":"Luo","year":"2025","journal-title":"Cell Death Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1592733","article-title":"Advancements and challenges in immunotherapy for gastric cancer: current approaches and future directions","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.32604\/or.2024.052207","article-title":"Immunotherapy in gastric cancer-A systematic review","volume":"33","author":"Santos","year":"2025","journal-title":"Oncol Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16930","article-title":"An overview of predictive biomarkers and detection approaches for immunotherapy response in GI Malignancies","volume":"40","author":"Chai","year":"2025","journal-title":"J Gastroenterol Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2016.25","article-title":"Metabolomics: beyond biomarkers and towards mechanisms","volume":"17","author":"Johnson","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s13046-023-02845-4","article-title":"Amino acid metabolism reprogramming: shedding new light on T cell anti-tumor immunity","volume":"42","author":"Zheng","year":"2023","journal-title":"J Exp Clin Cancer Res: CR"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008190","article-title":"Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer","volume":"12","author":"Zheng","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1025046","article-title":"Metabolomics profiling in prediction of chemo-immunotherapy efficiency in advanced non-small cell lung cancer","volume":"12","author":"Mei","year":"2022","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"106842","DOI":"10.4251\/wjgo.v17.i8.106842","article-title":"Lipid metabolism-related genes in gastric cancer: Exploring oncogenic pathways","volume":"17","author":"Amir","year":"2025","journal-title":"World J Gastrointest Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1186\/s12876-025-04136-y","article-title":"A Multi-marker model based on serum IL-10 predicts response to conversion immunochemotherapy in gastric cancer patients: a retrospective cohort study","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2011.335","article-title":"Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry","volume":"6","author":"Dunn","year":"2011","journal-title":"Nat Protoc"},{"key":"B18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/nprot.2012.135","article-title":"Global metabolic profiling of animal and human tissues via UPLC-MS","volume":"8","author":"Want","year":"2013","journal-title":"Nat Protoc"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2017.01.004","article-title":"Metabolomics: A primer","volume":"42","author":"Liu","year":"2017","journal-title":"Trends Biochem Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s11306-007-0082-2","article-title":"Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI)","volume":"3","author":"Sumner","year":"2007","journal-title":"Metabolomics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"171851","DOI":"10.1016\/j.scitotenv.2024.171851","article-title":"New sensitive tools to characterize meta-metabolome response to short- and long-term cobalt exposure in dynamic river biofilm communities","volume":"927","author":"Colas","year":"2024","journal-title":"Sci Total Environ"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/S2542-5196(23)00257-7","article-title":"In utero exposures to perfluoroalkyl substances and the human fetal liver metabolome in Scotland: a cross-sectional study","volume":"8","author":"Hy\u00f6tyl\u00e4inen","year":"2024","journal-title":"Lancet Planet Health"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02979-4","article-title":"Increased serum cholesterol and long-chain fatty acid levels are associated with the efficacy of nivolumab in patients with non-small cell lung cancer","volume":"71","author":"Karayama","year":"2022","journal-title":"Cancer Immunol Immunother: CII"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S450423","article-title":"Lipid metabolism as a potential target of liver cancer","volume":"11","author":"Wu","year":"2024","journal-title":"J Hepatocell Carcinoma"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v15.i4.617","article-title":"Lipid metabolism of hepatocellular carcinoma impacts targeted therapy and immunotherapy","volume":"15","author":"Feng","year":"2023","journal-title":"World J Gastrointest Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12931-025-03277-8","article-title":"Multi-omics unveils BCAA metabolism markers L-leucine and HMGCS1 as prognostic marker for immunotherapy efficacy in non-small cell lung cancer","volume":"26","author":"Dai","year":"2025","journal-title":"Respir Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1186\/s12967-025-06698-7","article-title":"Metabolic reprogramming in hepatocellular carcinoma: an integrated omics study of lipid pathways and their diagnostic potential","volume":"23","author":"Dai","year":"2025","journal-title":"J Trans Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-023-2353-0","article-title":"Bile acid signaling in the regulation of whole body metabolic and immunological homeostasis","volume":"67","author":"Jia","year":"2024","journal-title":"Sci China Life Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000914","article-title":"Regulatory Role and Biomarker Potential of Gut Microbiota Metabolites in the Progression of Metabolic dysfunction-associated steatotic liver disease (MASLD) to Hepatocellular Carcinoma (HCC)","volume":"16","author":"Che","year":"2025","journal-title":"Clin Trans Gastroenterol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1638352","article-title":"Interplay between bile acids, gut microbiota, and the tumor immune microenvironment: mechanistic insights and therapeutic strategies","volume":"16","author":"Tong","year":"2025","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41420-024-01865-z","article-title":"The effects of metabolism on the immune microenvironment in colorectal cancer","volume":"10","author":"Chen","year":"2024","journal-title":"Cell Death Discov"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/toxins12020090","article-title":"T-2 toxin induces oxidative stress, apoptosis and cytoprotective autophagy in chicken hepatocytes","volume":"12","author":"Yin","year":"2020","journal-title":"Toxins"},{"key":"B33","doi-asserted-by":"publisher","first-page":"105303","DOI":"10.1016\/j.jff.2022.105303","article-title":"Critical review on the immunomodulatory activities of carrot\u2019s \u03b2-carotene and other bioactive compounds","volume":"99","author":"Anjani","year":"2022","journal-title":"J Funct Foods"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25147603","article-title":"Bioactivity and bioavailability of carotenoids applied in human health: technological advances and innovation","volume":"25","author":"Bas","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1448750","article-title":"Corticosterone effects induced by stress and immunity and inflammation: mechanisms of communication","volume":"16","author":"Xu","year":"2025","journal-title":"Front Endocrinol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3067126","DOI":"10.1155\/2018\/3067126","article-title":"Impact of retinoic acid on immune cells and inflammatory diseases","volume":"2018","author":"Oliveira","year":"2018","journal-title":"Mediators Inflammation"},{"key":"B37","doi-asserted-by":"publisher","first-page":"104331","DOI":"10.1016\/j.phrs.2019.104331","article-title":"The potential of retinoids for combination therapy of lung cancer: Updates and future directions","volume":"147","author":"Tripathi","year":"2019","journal-title":"Pharmacol Res"},{"key":"B38","article-title":"Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors","volume":"8","author":"Zhang","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"100290","DOI":"10.1016\/j.metop.2024.100290","article-title":"Clinical metabolomics: Useful insights, perspectives and challenges","volume":"22","author":"Dalamaga","year":"2024","journal-title":"Metab Open"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1714472\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:00:16Z","timestamp":1771927216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1714472\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2026.1714472"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1714472","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"article-number":"1714472"}}